You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Scanfil Q3’23: No Surprises
The overall picture of Scanfil’s Q3 report was somewhat neutral relative to the lowered expectations, as the result was in line with our expectations and the report did not dispel the uncertainty surrounding next year’s outlook. Head of Research Antti Viljakainen comments in an interview.
Content:
00:00 Intro
00:12 Q3 in a nutshell
01:18 Estimates
01:48 Market situation and comparison to peers
02:36 Market sentiment
03:33 Valuation
05:00 Institutional ownership
Herantis Pharma as an Investment | Life Science Night Dec. 2, 2024
Aiforia as an Investment | Life Science Night Dec. 2, 2024
Faron Pharmaceuticals as an Investment | Life Science Night Dec. 2, 2024
Life Science Companies as Investments | Life Science Night Dec. 2, 2024
Life Science Night | December 2, 2024
Titta på alla videor